Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Carvykti
Pharma
Gilead reports 7% sales decline for CAR-Ts Yescarta, Tecartus
Gilead reported that sales of its cell therapies were down 7%, with blockbuster Yescarta declining by 5%.
Kevin Dunleavy
Aug 8, 2025 11:40am
J&J, Legend debut first TV ad for multiple myeloma med Carvykti
Jul 30, 2025 2:56pm
FDA removes barrier to CAR-Ts; move likely to boost uptake
Jun 27, 2025 11:14am
J&J, Legend to invest $150M in Belgium cell therapy facility
Mar 12, 2025 2:15pm
Should BeiGene or Legend sell itself in 2025?
Jan 9, 2025 9:15am
FDA revisits CAR-T boxed warning on secondary cancers: Marks
Nov 1, 2024 10:30am
